News | January 29, 2014

G-CON Manufacturing Selected To Build ISO 5 POD For Instituto Butantan

Request Information
gI_63541_G-CON Manufacturing 300

G-CON to build, deliver, and install a flexible cleanroom POD in Sao Paulo, Brazil for use in clinical production of recombinant BCG.

College Station, TX (PRWEB) - G-CON Manufacturing, builder of flexible, autonomous bioprocessing cleanroom solutions, has been selected to build an ISO Class 5 POD for Instituto Butantan, a biomedical research center linked to the Sao Paulo Secretary of State for Health. Instituto Butantan, based in Sao Paulo, Brazil, ordered the POD for use in the clinical production of recombinant BCG, a product intended to be an improved treatment for bladder cancer.

Instituto Butantan is purchasing a standard size POD that is 12’W x 42’L x 11.5’H (3.66m x 12.80m x 3.51m). The POD is designed to provide approximately 312 sq. ft. (29.0 sqm) of cleanroom space with a custom configuration for the filling and finishing of the clinical product. This POD will be the first project to be delivered internationally by G-CON. G-CON will provide the shipping, delivery and installation of the POD.

G-CON is also working with Instituto Butantan on other opportunities for applying PODs to help meet their future manufacturing needs. As such, the POD being purchased now may pave the way for future international installations.

About G-CON
G-CON provides the resources and experience to transform the industry by providing unmatched manufacturing flexibility. G-CON’s founders have significant experience in designing, building, operating, and maintaining a variety of traditional biomanufacturing facilities. They are familiar with the excessive cost to build, lack of flexibility, and high expense to maintain these traditional facilities and have leveraged this experience to create the G-CON POD™ solution. Moreover, the G-CON team understands that future facility designs must be multipurpose and repurposable, instead of fixed and specialized with ineffective capacity utilization. For more information, please visit the Company's website at http://www.gconbio.com.

SOURCE: PRWeb

View original release here: http://www.prweb.com/releases/2014/01/prweb11529601.htm